Predicted protein targets (top 1)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ACHE | P22303 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL22342112 | 0.81 | HDAC1 (0.32) | — | |
| SCHEMBL8847064 | 0.75 | ACHE (0.35) | ACHE | |
| Phosphine SCHEMBL27772308 | 0.72 | ACHE (0.33) | ACHE | |
| SCHEMBL24973953 | 0.72 | RAPGEF4 (0.33) | — | |
| SCHEMBL22601212 | 0.70 | — | — | |
| SCHEMBL13891480 | 0.67 | RAPGEF4 (0.37) | ACHE | |
| SCHEMBL6299270 | 0.67 | RAPGEF4 (0.37) | ACHE | |
| SCHEMBL30754183 | 0.67 | RAPGEF4 (0.37) | ACHE | |
| SCHEMBL13980078 | 0.67 | ACHE (0.33) | ACHE | |
| SCHEMBL5616902 | 0.66 | ACHE (0.42) | ACHE |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230348642-A1 | Ethylene-Alpha-Olefin-Diene Monomer Copolymers Obtained Using Transition Metal Bis(Phenolate) Catalyst Complexes and Homogeneous Process for Production Thereof | EXXONMOBIL CHEMICAL PATENTS INC (US) | 2023-11-02 | — | — | US | disclosed |
| US-20210179537-A1 | Non-Coordinating Anion Type Activators Containing Cation Having Aryldiamine Groups and Uses Thereof | EXXONMOBIL CHEMICAL PATENTS INC. | 2021-06-17 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20210179537-A1 | Non-Coordinating Anion Type Activators Containing Cation Having Aryldiamine Groups and Uses Thereof | MYB, YAP1, AADAC | ACHE 1200/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.